Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FMISO PET/CT in NSCLC
NCT02016872Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2013
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of fluoromisonidazole in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Difference Between Two Baseline 18F-FMISO Scans at 3 days and Progression-Free Survival at 3 years. Started Dec 2013; status: completed.
02
Drugs
fluoromisonidazole
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02016872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02016872.